David Lee, Servier Pharmaceuticals CEO
October 7, 2022 02:40 PM EDT
Pharma
Marketing

Servi­er adds a 's­mile' to its brand while set­ting am­bi­tious on­col­o­gy goals

Nicole DeFeudis

Editor

Servi­er has dropped bil­lions of dol­lars over the past sev­er­al years with the goal of be­com­ing a top play­er in hard-to-treat can­cers. Now it’s set­ting …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times